Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

Autor: Blank CU; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl., Rozeman EA; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Fanchi LF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Sikorska K; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Wiel B; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kvistborg P; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Krijgsman O; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Braber M; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Philips D; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Broeks A; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Thienen JV; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Mallo HA; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Adriaansz S; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Ter Meulen S; Surgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Pronk LM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Grijpink-Ongering LG; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bruining A; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gittelman RM; Adaptive Biotechnologies, Seattle, WA, USA., Warren S; NanoString Technologies, Inc., Seattle, WA, USA., van Tinteren H; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Peeper DS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JBAG; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Akkooi ACJ; Surgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schumacher TN; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. t.schumacher@nki.nl.
Jazyk: angličtina
Zdroj: Nature medicine [Nat Med] 2018 Nov; Vol. 24 (11), pp. 1655-1661. Date of Electronic Publication: 2018 Oct 08.
DOI: 10.1038/s41591-018-0198-0
Abstrakt: Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free survival of stage III melanoma patients 1,2 . In stage IV disease, the combination of ipilimumab + nivolumab is superior to ipilimumab alone and also appears to be more effective than nivolumab monotherapy 3 . Preclinical work suggests that neoadjuvant application of checkpoint inhibitors may be superior to adjuvant therapy 4 . To address this question and to test feasibility, 20 patients with palpable stage III melanoma were 1:1 randomized to receive ipilimumab 3 mg kg -1 and nivolumab 1 mg kg -1 , as either four courses after surgery (adjuvant arm) or two courses before surgery and two courses postsurgery (neoadjuvant arm). Neoadjuvant therapy was feasible, with all patients undergoing surgery at the preplanned time point. However in both arms, 9/10 patients experienced one or more grade 3/4 adverse events. Pathological responses were achieved in 7/9 (78%) patients treated in the neoadjuvant arm. None of these patients have relapsed so far (median follow-up, 25.6 months). We found that neoadjuvant ipilimumab + nivolumab expand more tumor-resident T cell clones than adjuvant application. While neoadjuvant therapy appears promising, with the current regimen it induced high toxicity rates; therefore, it needs further investigation to preserve efficacy but reduce toxicity.
Databáze: MEDLINE
Externí odkaz: